Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

Maxime DougadosJames Cheng-Chung WeiRobert LandewéJoachim SieperXenofon BaraliakosFilip Van den BoschWalter P MaksymowychJoerg ErmannJessica A WalshTetsuya TomitaAtul DeodharDésirée van der HeijdeXiaoqi LiFangyi ZhaoClinton C BertramGaia GalloHilde CarlierLianne S Gensler2026-01-302026-01-302020-0210.1136/annrheumdis-2019-216118https://scholars.csmu.edu.tw/handle/123456789/3950Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)journal-article